Výsledky vyhledávání

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Publikováno v: British Journal of Cancer

Method: The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ead51dcbe7c0874045d9ab40685c07
https://doi.org/10.1038/bjc.2011.257

Zobrazit plný text záznamu

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Autor: Martin Gore, Poulam M. Patel, D. Beirne, Karen Thomas, James Larkin, S Bate, Tim Eisen, I Gibbens, S A Hughes

Publikováno v: British Journal of Cancer

Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6b14010cebf50e44c8b7732df546ac
https://doi.org/10.1038/sj.bjc.6603503

Zobrazit plný text záznamu

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Autor: Richard Marais, Ronit Simantov, Katherine L. Nathanson, I Gibbens, Chenghua Xia, Stan B. Kaye, M Poulin-Costello, Brian Schwartz, S Hackett, Lynn M. Schuchter, Tim Eisen, Keith T. Flaherty, Martin Gore, Tanya Ahmad, Peter O'Dwyer, M. G. James, Mark J. Ratain

Publikováno v: British Journal of Cancer

The effects of sorafenib--an oral multikinase inhibitor targeting the tumour and tumour vasculature--were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II randomised discontinuation trial (RDT). Enrolled patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32e2c1c35de9271ec3f658a121c7c34
https://doi.org/10.1038/sj.bjc.6603291

Zobrazit plný text záznamu

Attitudes to chemotherapy in patients with ovarian cancer

Autor: Michael V. Seiden, I. Gibbens, Ursula A. Matulonis, K. Olson, M. E. Gore, Fiona L Dignan, Richard T. Penson, Hang Lee, C.J. Gallagher

Publikováno v: Gynecologic Oncology. 94:427-435

Recurrent ovarian cancer (OVCA) has become the model for cancer as a chronic disease, yet little is known about what motivates patients and physicians in treatment choices.We investigated the attitudes of patients with epithelial OVCA and staff towar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ac4b28df5455ab5517b4e36dc93ad0
https://doi.org/10.1016/j.ygyno.2004.05.034

Zobrazit plný text záznamu

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

Autor: Martin Gore, Christian Rothermundt, C. Keyzor, T Ahmad, I Gibbens, R. Hubner, T Habeshaw, Stan B. Kaye

Publikováno v: British Journal of Cancer

Platinum-based combination chemotherapy has been proven to be superior to single-agent platinum in the treatment of relapsed ovarian cancer after a treatment-free interval of more than 6 months. A response rate of 41% was previously reported by our g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0d993487b220a19414adf7899a4f27
https://pubmed.ncbi.nlm.nih.gov/16306873

Zobrazit plný text záznamu

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

Autor: Timothy J. Perren, O Pizzada, Stan B. Kaye, Geoffrey Hall, Martin Gore, C Cole, C Moss, Roger A'Hern, Mark Harries, A. Jenkins, M. Everard, R. N. H. Shah, I Gibbens

Publikováno v: British Journal of Cancer
Scopus-Elsevier

A total of 53 women with chemotherapy-naïve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the curve 7 every 3 weeks, followed by four cycles of paclitaxel 70 mg m(-2) (days 1, 8, and 15) and gemcitabine 1000 mg m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0fb413343086d3f5e5ca3d42f0df60

Zobrazit plný text záznamu

Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients

Autor: Timothy Eisen, M. E. Gore, L. Bergamini, I Gibbens, Tanya Ahmad, Brian Schwartz, Richard Marais, M. G. James

Publikováno v: Journal of Clinical Oncology. 23:7508-7508

7508 Background: BAY 43–9006 (BAY) prevents tumor cell proliferation and angiogenesis via blockade of the RAF/MEK/ERK pathway at the level of RAF (RAF-1, wild-type B-RAF, V599E B-RAF) kinase and inhibition of the receptor tyrosine kinases VEGFR-2 a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71e403b92cf2d4696dc868a85abc796c
https://doi.org/10.1200/jco.2005.23.16_suppl.7508

Zobrazit plný text záznamu

Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial

Autor: C. Keyzor, M. E. Gore, I Gibbens, R. Hubner, Stan B. Kaye, A. Rigg, Tanya Ahmad, A. Prouse

Publikováno v: Journal of Clinical Oncology. 22:5109-5109

5109 Background: We have previously shown the combination of epirubicin, cisplatin, and prolonged infusional 5-fluorouracil (5-FU) is active in relapsed epithelial ovarian cancer (EOC). Capecitabin...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9767482e0df9418d8b32dc98bf4f919
https://doi.org/10.1200/jco.2004.22.90140.5109

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání